The Health Impact of Getting to Glucose, Systolic Blood Pressure (SBP), and Serum Cholesterol Goals in Patients Newly Diagnosed with Type 2 Diabetes Mellitus (T2DM) in Canada

2012 ◽  
Vol 36 (5) ◽  
pp. S48
Author(s):  
Anna R. Teschemaker ◽  
Pierre Johansen ◽  
Nicole C. Brazier ◽  
Cheryl Neslusan ◽  
Michael Willis
Circulation ◽  
2014 ◽  
Vol 130 (suppl_2) ◽  
Author(s):  
Pablo Lapuerta ◽  
Paul Strumph ◽  
Philip Banks ◽  
Ikenna Ogbaa ◽  
Brian Zambrowicz ◽  
...  

Introduction: Selective sodium-glucose cotransporter 2 (SGLT2) inhibitors target only the kidney, and they have reduced efficacy when patients with type 2 diabetes mellitus (T2DM) have renal impairment (RI). LX4211 blocks sodium and glucose absorption in the gastrointestinal tract by inhibition of SGLT1, and it enhances urinary sodium and glucose excretion in the urine through inhibition of SGLT2. The dual SGLT1/2 action of LX4211 was anticipated to reduce systolic blood pressure (SBP) in addition to improving glucose control in the setting of RI. Methods: This analysis explored the effect of LX4211 on SBP in a clinical trial of patients with T2DM and moderate to severe RI. Patients (N=31) were randomly assigned to be treated with LX4211 (400 mg, N=16) or placebo (N=15) qd for 7 consecutive days. Postprandial glucose levels after a standard high glucose meal served as the primary measure of pharmacodynamic activity. Baseline and Day 8 trough SBP measures were each an average of 3 seated assessments. Results: Mean baseline characteristics included age 66.4 years, estimated glomerular filtration rate (eGFR) 43.4 mL/min/1.73 m 2 , and SBP 130.9 mmHg. Postprandial glucose area under the curve (sampled from pre-dose to 4 hours post meal) was reduced from Baseline to Day 7 by 169.3 mg*hr/dL on LX4211 compared to placebo (p=0.003). Day 8 SBP reductions were 11.4 mmHg on LX4211 and 0.0 mmHg on placebo (p=0.045 for difference between groups). Patients with greater RI (eGFR <45 mL/min/1.73 m2) treated with LX4211 (N=6) had a 10.5 mmHg SBP reduction compared to 0.3 mmHg on placebo (N=9). The difference between seated and standing SBP did not change with LX4211 (0.0 mmHg change, Day 8 vs. Baseline). There were no reports of hypotension, hypovolemia, no serious adverse events, and no patient discontinued due to an adverse event. Mild hypoglycemia was reported in 1 LX4211 patient compared to 2 placebo patients. Conclusions: LX4211 may reduce SBP and enhance glycemic control in T2DM patients with moderate to severe RI.


2021 ◽  
Vol 1 (4) ◽  
pp. 307-314
Author(s):  
Toni Prasetia ◽  
Firhat Esfandiari ◽  
Sandhy Arya Pratama ◽  
Ikbal Zaenur Ridwan

ABSTRACT: RELATIONSHIP BETWEEN SYSTOLIC BLOOD PRESSURE AND HDL CHOLESTEROL LEVELS IN TYPE 2 DIABETES MELLITUS PATIENTS IN ARAFAH CLINIC, CENTRAL LAMPUNG Background: Hypertension is a major risk factor for type 2 Diabetes Mellitus, hypertension can make cells insensitive to insulin, so blood sugar levels can also be disrupted. Dyslipidemia causes constriction in blood vessels or atherosclerosis which can aggravate hypertension or diabetes mellitus. Meanwhile, the function of HDL in transporting bad cholesterol also causes blood vessels to dilate due to increased NO production. Objective: To find out the relationship between systolic blood pressure and HDL cholesterol levels in type 2 diabetes mellitus patients at the Arafah Clinic, Central Lampung, 2020. Method: This type of research used in this research is descriptive-analytic with cross-sectional design. The sampling technique was total sampling. Respondents in this study were patients with Type 2 Diabetes Mellitus at the Arafah Clinic in Central Lampung in 2020 Results: Based on the results of the chi-square statistical test, it was found that there was no relationship with the results of p = 0.898 (p> 0.05). Conclusion: There is no correlation between systolic blood pressure and HDL cholesterol levels in type 2 diabetes mellitus patients at the Arafah Clinic, Central Lampung in 2020. Keywords: Diabetes Mellitus type 2, Systolic Blood Pressure, HDL   INTISARI: HUBUNGAN TEKANAN DARAH SISTOLIK DENGAN KADAR KOLESTEROL HDL PADA PASIEN DIABETES MELLITUS TIPE 2 DI KLINIK ARAFAH LAMPUNG TENGAH Latar Belakang: Hipertensi merupakan faktor risiko utama untuk terjadinya Diabetes Melitus tipe 2, hipertensi dapat membuat sel tidak sensitif terhadap insulin, maka kadar gula di dalam darah juga dapat mengalami gangguan. Dislipidimia menyebabkan terjadinya penyempitan dalam pembuluh darah atau aterosklerosis yang dapat memperberat kondisi hipertensi ataupun diabetes mellitus. Sedangkan fungsi HDL mengangkut kolesterol jahat juga menyebabkan pembuluh darah bisa berdilatasi karena produksi NO yang meningkat.Tujuan: Untuk mengetahui Hubungan Antara Tekanan Darah Sistolik dengan Kadar HDL Kolesterol pada pasien Diabetes Melitus tipe 2 di Klinik Arafah Lampung Tengah Tahun 2020.Metode: Jenis penelitian yang digunakan dalam penelitian ini adalah deskriptif analitik dengan desain cross sectional. Teknik pengambilan sampel berupa total sampling. Responden dalam penelitian ini adalah pasien Diabetes Melitus tipe 2 di Klinik Arafah Lampung Tengah.Hasil: Berdasarkan hasil uji statistic chi-square didapatkan tidak terdapat hubungan dengan hasil p=0,898 (p>0,05).Kesimpulan: Tidak terdapat Hubungan Antara Tekanan Darah Sistolik dengan Kadar HDL Kolesterol pada pasien Diabetes Melitus tipe 2 di Klinik Arafah Lampung Tengah tahun 2020. Kata Kunci     : Diabetes Melitus tipe 2, Tekanan Darah Sistolik, HDL


2021 ◽  
Author(s):  
Nigusie Gashaye Shita ◽  
Ashagrie Sharew Iyasu

Abstract Background: Type 2 diabetes mellitus patients with hyperglycemia for a long period are significant causes of mortality and morbidity worldwide. Studying the predictors of glycemic control helps to minimize deaths and the development of acute and chronic diabetes complication. Hence, this study aims to assess predictors of glycemic control among patients with Type 2 diabetes in Ethiopia.Methods: A retrospective cohort study was conducted among type 2 Diabetes mellitus (T2DM) patients enrolled between December 2011 and December 2012 at Debre Markos and Felege Hiwot Referral Hospital. A total of 191 T2DM patients were included in the study meets the eligibility criteria. A generalized linear mixed model was employed. Results: The prevalence of good glycemic control among type 2 diabetes patients was 58.4% whereas 23.25% of the variation was explained in the fitted model due to adding the random effects. The significance predictors of glycemic control among patients with Type 2 diabetes at 95% confidence level were reside in rural(0.454, 0.614)), patients age 38-50, 51-59 and 60-66 years(1.267,1.776), (1.057,1.476) and (1.004, 1.403), respectively, Proteinuria Positive (1.211, 1.546), diastolic blood pressure ≥90 (1.101, 1.522), systolic blood pressure ≥140 (1.352, 1.895), creatinine (0.415, 0.660), duration per visit (0.913, 0.987), duration since diagnosis (0.985, 0.998), weight 78-88(0.603, 0.881).Conclusion: The level of glycemic control among type 2 diabetes patients was poor. Type 2 diabetes mellitus patients having higher age of the patient, higher weight, reside in rural, longer duration of T2DM since diagnosis, longer duration of type 2DM per visit, increase creatinine, positive protein urea, diastolic blood pressure≥90, and systolic blood pressure≥140 were significant predictors of poor glycemic control among type 2 DM patients. During diabetic patients follow up, clinicians should give appropriate attention to these significant variables for good glycemic control since it is the main goal of diabetes management.


Sign in / Sign up

Export Citation Format

Share Document